Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus GLYCOPYRRONIUM TOSYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus GLYCOPYRRONIUM TOSYLATE.
CANTIL vs GLYCOPYRRONIUM TOSYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), inhibiting parasympathetic nerve impulses. Blocks the action of acetylcholine at autonomic effector sites innervated by postganglionic cholinergic nerves, reducing salivary, bronchial, and gastric secretions, and relaxing smooth muscle.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
Glycopyrronium tosylate: 1-2 mg orally 2-3 times daily; maximum 8 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life: 0.6–1.2 hours in adults with normal renal function; prolonged in renal impairment (up to 3–4 hours). Clinically, duration of action is longer than half-life due to high receptor affinity.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Renal: 85% unchanged; biliary/fecal: ~5% as metabolites and unchanged drug; elimination primarily via glomerular filtration and tubular secretion.
Category C
Category C
Anticholinergic / Antispasmodic
Anticholinergic